ClaroNav, a surgical navigation and photogrammetry systems developer, has received expanded approval from the US Food and Drug Administration (FDA) for its Navident EVO system to include guided endodontics.
Navident EVO is a dental-surgical navigation technology. It is said to improve precision and enhance results for hard-tissue dental surgeries.
The technology uses advanced navigation technology and real-time visual guidance for minimally invasive endodontic treatments.
According to the Canada-based ClaroNav, this approach preserves tooth structure and improves efficiency for both dentists and patients.
It provides less invasive access to calcified and hidden canals while preserving tooth structure. Additionally, it saves time when locating and accessing canals.
Overall, the introduction of the endodontic mode within the Navident EVO system is said to enhance clinicians’ ability to detect, diagnose, and plan treatments before dynamic navigation.
Navident EVO utilises detailed Cone-beam computed tomography systems (CBCT) scans to improve precision and accuracy. This helps in preoperative planning, ensuring precise placements in implant and endodontic surgeries.
It supports minimally invasive techniques, resulting in smaller incisions that reduce patient discomfort and speed up recovery times.
Navident EVO is also said to streamline workflows, thereby simplifying complex procedures and enhancing efficiency with its intuitive interface.
Overall, its advanced capabilities lead to less invasive surgeries, quicker recoveries, and improved safety and comfort for patients, said the company.
ClaroNav dental president Jason Pardo said: “We are very proud to provide the endodontic practitioners and patients in the United States with this toothsaving and time-saving technology.
“The ClaroNav Dental team will continue to expand its scope of indications and its range of applications to benefit dental clinicians and their patients around the world.”
The Navident EVO system is based on ClaroNav’s Navident, which was cleared in the US in 2016 for guiding dental implant treatment.
To date, Navident has expanded its protocols to include fully edentulous implant cases, endodontic treatments, and other complex indications worldwide.
